Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients

AIDS Patient Care and STDs

Volumn 21, Issue 4, 2007, Pages 247-251

  Chiu, Yi Lin ^a   Klein, Cheri E ^a   Woodward, William C ^a   King, Kathryn R ^a   Naylor, Christian ^a   Awni, Walid ^a   Brun, Scott ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; PROTON PUMP INHIBITOR; RITONAVIR; TUMS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; ANTACIDS; AREA UNDER CURVE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PYRIMIDINONES; RANDOMIZED CONTROLLED TRIALS; RITONAVIR;

EID: 34247585526     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0120     Document Type: Article

References (15)

1. O'Brien M, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34:407-414.
2. Luber A, Garg V, Gharakhanian S; Vertex HIV Program Team. Survey of medication used by HIV-infected patients that affect gastrointestinal acidity and potential for negative drug interactions with HAART [Poster 206]. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK: November 14-18, 2004.
3. Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother 2005;49:467-469.
4. Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetic effect of omeprazole on atazanavir co-administered with ritonavir in healthy subjects [Poster 658]. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February 22-25, 2005.
5. Guiard-Schmid J-B, Poirier J-M, Bonnard P, et al. Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir. AIDS 2005;19:1937-1938.
6. Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 2006;26:341-346.
7. Burger DM, Hugen PWH, Kroon FP, et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS 1998;12:2080-2082.
8. Rublein JC, Donovan, BJ, Hollowell, SB, et al. Effect of omeprazole on the plasma concentrations of indinavir in HIV-negative subjects [Abstract A-1611]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: September 14-17, 2003.
9. Winston A, Back D, Fletcher C. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS 2006;20:1401-1406.
10. Agarwala S, Eley T, Villegas C, et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects [Abstract 11]. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Quebec, Canada: April 28-30, 2005.
11. Khanlou H, Farthing C. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. J Acquir Immune Defic Syndr 2005;39:503.
12. Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol 1990;12(Suppl 2):S54-63.
13. Humphries TJ, Merritt GJ. Drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999;13(Suppl 3):18-26.
14. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial. J Infect Dis 2004;189:265-272.
15. Johnson M, Gathe J, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared to a twice-daily lopinavir/ritonavir-based regimen in antiretroviral-naïve patients. J Acquir Immune Defic Syndr 2006;43:153-160.